Disease progression of 213 patients hospitalized with Covid-19 in the Czech Republic in March-October 2020: An exploratory analysis.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
24
12
2020
accepted:
15
07
2021
entrez:
6
10
2021
pubmed:
7
10
2021
medline:
14
10
2021
Statut:
epublish
Résumé
We collected a multi-centric retrospective dataset of patients (N = 213) who were admitted to ten hospitals in Czech Republic and tested positive for SARS-CoV-2 during the early phases of the pandemic in March-October 2020. The dataset contains baseline patient characteristics, breathing support required, pharmacological treatment received and multiple markers on daily resolution. Patients in the dataset were treated with hydroxychloroquine (N = 108), azithromycin (N = 72), favipiravir (N = 9), convalescent plasma (N = 7), dexamethasone (N = 4) and remdesivir (N = 3), often in combination. To explore association between treatments and patient outcomes we performed multiverse analysis, observing how the conclusions change between defensible choices of statistical model, predictors included in the model and other analytical degrees of freedom. Weak evidence to constrain the potential efficacy of azithromycin and favipiravir can be extracted from the data. Additionally, we performed external validation of several proposed prognostic models for Covid-19 severity showing that they mostly perform unsatisfactorily on our dataset.
Identifiants
pubmed: 34613965
doi: 10.1371/journal.pone.0245103
pii: PONE-D-20-40463
pmc: PMC8494367
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0245103Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Eur J Intern Med. 2020 Dec;82:38-47
pubmed: 32859477
Nat Med. 2020 Nov;26(11):1708-1713
pubmed: 32934372
Epidemiology. 1999 Jan;10(1):37-48
pubmed: 9888278
Infect Prev Pract. 2020 Sep;2(3):100061
pubmed: 34316558
PLoS Med. 2013;10(2):e1001381
pubmed: 23393430
Med (N Y). 2020 Dec 18;1(1):105-113.e4
pubmed: 32838353
BMJ. 2020 Jul 30;370:m2980
pubmed: 32732190
BMJ. 2020 Oct 22;371:m3939
pubmed: 33093056
Crit Care. 2020 Mar 18;24(1):108
pubmed: 32188484
BMJ. 2006 May 6;332(7549):1080
pubmed: 16675816
Int J Antimicrob Agents. 2020 Oct;56(4):106144
pubmed: 32853673
Perspect Psychol Sci. 2016 Sep;11(5):702-712
pubmed: 27694465
Ther Innov Regul Sci. 2021 Jan;55(1):197-211
pubmed: 32870460
JAMA. 2021 Mar 23;325(12):1185-1195
pubmed: 33635310
Epidemiology. 2019 Jul;30(4):517-520
pubmed: 31033691
BMJ. 2020 Apr 7;369:m1328
pubmed: 32265220
NPJ Digit Med. 2020 Aug 19;3:109
pubmed: 32864472
BMC Bioinformatics. 2011 Mar 17;12:77
pubmed: 21414208
Am J Epidemiol. 2019 Aug 1;188(8):1569-1577
pubmed: 31063192
Eur Respir J. 2020 Dec 24;56(6):
pubmed: 32978307
J Clin Epidemiol. 2016 Nov;79:70-75
pubmed: 27237061
BMC Med Res Methodol. 2019 Feb 7;19(1):28
pubmed: 30732587
J Clin Endocrinol Metab. 2020 Aug 1;105(8):
pubmed: 32474598
J Med Virol. 2021 Jan;93(1):463-471
pubmed: 32720702
JAMA. 2020 May 12;323(18):1824-1836
pubmed: 32282022
Biometrics. 2003 Dec;59(4):947-54
pubmed: 14969473
Nat Med. 2020 Oct;26(10):1636-1643
pubmed: 32839624
Cells. 2020 Sep 29;9(10):
pubmed: 33003471